Research Analysts’ Weekly Ratings Changes for IDEAYA Biosciences (IDYA)

IDEAYA Biosciences (NASDAQ: IDYA) recently received a number of ratings updates from brokerages and research firms:

• 11/18/2024 – IDEAYA Biosciences is now covered by analysts at Stephens. They set an “overweight” rating and a $51.00 price target on the stock.
• 11/5/2024 – IDEAYA Biosciences was downgraded by analysts at Leerink Partners from an “outperform” rating to a “market perform” rating. They now have a $27.00 price target on the stock, down previously from $41.00.
• 11/5/2024 – IDEAYA Biosciences was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 11/4/2024 – IDEAYA Biosciences had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $52.00 price target on the stock.
• 10/29/2024 – IDEAYA Biosciences had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $53.00 price target on the stock.
• 10/24/2024 – IDEAYA Biosciences is now covered by analysts at UBS Group AG. They set a “buy” rating and a $50.00 price target on the stock.
• 10/15/2024 – IDEAYA Biosciences is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 9/24/2024 – IDEAYA Biosciences had its price target lowered by analysts at Wedbush from $54.00 to $52.00. They now have an “outperform” rating on the stock.
• 9/24/2024 – IDEAYA Biosciences had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock.

IDEAYA Biosciences Stock Up 4.2 %

Shares of IDYA opened at $26.60 on Friday. The company has a 50 day moving average of $30.60 and a two-hundred day moving average of $35.94. IDEAYA Biosciences, Inc. has a twelve month low of $25.20 and a twelve month high of $47.74. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -11.42 and a beta of 0.86.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter in the previous year, the business earned ($0.46) earnings per share. On average, sell-side analysts expect that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current year.

Institutional Investors Weigh In On IDEAYA Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC grew its position in IDEAYA Biosciences by 12.1% during the third quarter. FMR LLC now owns 12,635,653 shares of the company’s stock valued at $400,297,000 after buying an additional 1,365,570 shares during the period. RA Capital Management L.P. acquired a new position in shares of IDEAYA Biosciences during the 3rd quarter worth approximately $42,681,000. Janus Henderson Group PLC raised its stake in shares of IDEAYA Biosciences by 26.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock worth $163,518,000 after buying an additional 1,086,356 shares during the period. Vanguard Group Inc. grew its stake in IDEAYA Biosciences by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company’s stock valued at $182,355,000 after acquiring an additional 679,985 shares during the period. Finally, Jennison Associates LLC grew its stake in IDEAYA Biosciences by 136.6% in the 3rd quarter. Jennison Associates LLC now owns 972,266 shares of the company’s stock valued at $30,801,000 after acquiring an additional 561,404 shares during the period. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.